Helping patients with bronchiectasiscystic fibrosisCOPDasthma

MCC Therapeutics, Inc. is developing novel therapeutics to improve mucociliary clearance (MCC) in people with various airway obstructive diseases.

The therapeutics are based on the discovery made by its founders at Stanford University, of potent synergism between cholinergic-adrenergic agonists

Technology

We advance the discovery of a novel, synergistic increase of airways mucociliary clearance by a combination of beta-adrenergic and cholinergic agonists.

Drug

MCCSA2- Inhaled Formoterol Fumarate and Methacholine Chloride

Clinical Trials

We conducted a Phase 1 single ascending dose study in human subjects at Stanford Medical Center.

News & Publications

  • June 24, 2026||News||

    MCC Therapeutics, Inc. will present Phase 1 Clinical Results of MCCSA2 at the World Bronchiectasis Conference (WBC2026) in Hanover, Germany

  • June 5, 2026||News||

    MCC Therapeutics announces the Publication of its Scientists’ Paper in the Journal of Clinical Investigation

  • October 7, 2025||News||

    New hope from old drugs for cystic fibrosis: startup explores combination therapy

  • September 15, 2025||Annual Update||

    Annual Update for 2025